Published in J Exp Med on August 29, 2005
The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. Lymphat Res Biol (2010) 1.27
Recruitment of the inflammatory subset of monocytes to sites of ischemia induces angiogenesis in a monocyte chemoattractant protein-1-dependent fashion. J Leukoc Biol (2008) 1.20
Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas. Proc Natl Acad Sci U S A (2008) 1.15
Acral lesions in tuberous sclerosis complex: insights into pathogenesis. J Am Acad Dermatol (2010) 1.13
Gene expression analysis of tuberous sclerosis complex cortical tubers reveals increased expression of adhesion and inflammatory factors. Brain Pathol (2009) 1.12
Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. Hum Mol Genet (2013) 1.06
Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene. J Immunol (2009) 1.05
Human TSC2-null fibroblast-like cells induce hair follicle neogenesis and hamartoma morphogenesis. Nat Commun (2011) 0.93
Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Respir Med (2010) 0.92
Resveratrol and its synthetic derivatives exert opposite effects on mesothelial cell-dependent angiogenesis via modulating secretion of VEGF and IL-8/CXCL8. Angiogenesis (2012) 0.92
Lymphangioleiomyomatosis and TSC2-/- cells. Lymphat Res Biol (2010) 0.87
Lymphatic involvement in lymphangioleiomyomatosis. Ann N Y Acad Sci (2008) 0.85
Involvement of lymphatics in lymphangioleiomyomatosis. Lymphat Res Biol (2009) 0.85
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia. Vasc Cell (2012) 0.80
Application of angiogenesis to clinical dermatology. Adv Dermatol (2008) 0.79
The role of chemokines in migration of metastatic-like lymphangioleiomyomatosis cells. Crit Rev Immunol (2010) 0.79
Feasibility of immunotherapy for lymphangioleiomyomatosis. Am J Pathol (2009) 0.76
Nipple Angiofibromas with Loss of TSC2 Are Associated with Tuberous Sclerosis Complex. J Invest Dermatol (2015) 0.76
EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS. Expert Opin Orphan Drugs (2016) 0.75
Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation. Cancer Res (2017) 0.75
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol (2004) 9.71
Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol (2004) 7.59
Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A (2003) 6.06
Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol (1998) 5.47
Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood (2000) 4.34
TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell (2003) 4.13
TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem Sci (2004) 3.56
Factor XIIIa is expressed by fibroblasts in fibrovascular tumors. J Cutan Pathol (1989) 2.30
Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. J Am Acad Dermatol (2002) 2.05
Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell (2004) 1.98
Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res (2003) 1.90
Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci U S A (1998) 1.59
Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol (2004) 1.49
Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J Am Soc Nephrol (2004) 1.44
The cutaneous features of tuberous sclerosis: a population study. Br J Dermatol (1996) 1.40
Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet (2001) 1.39
Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human gastric carcinomas. Int J Oncol (2003) 1.29
Keratinocyte-derived monocyte chemoattractant protein 1 (MCP-1): analysis in a transgenic model demonstrates MCP-1 can recruit dendritic and Langerhans cells to skin. J Invest Dermatol (1995) 1.28
Expression of ICAM-1, TNF-alpha, NF kappa B, and MAP kinase in tubers of the tuberous sclerosis complex. Neurobiol Dis (2003) 1.26
Migration of human blood dendritic cells across endothelial cell monolayers: adhesion molecules and chemokines involved in subset-specific transmigration. J Leukoc Biol (2003) 1.22
Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res (2003) 1.21
Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin. Hum Mol Genet (2001) 1.16
HSP47 is a useful marker for skin fibroblasts in formalin-fixed, paraffin-embedded tissue specimens. J Cutan Pathol (2004) 1.14
Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis. J Cutan Pathol (2001) 1.11
Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1 -independent pathway. Atherosclerosis (2004) 1.05
Transgenic expression of dominant negative tuberin through a strong constitutive promoter results in a tissue-specific tuberous sclerosis phenotype in the skin and brain. J Biol Chem (2004) 1.04
Distribution and mRNA expression of insulin-like growth factor system in pulmonary lymphangioleiomyomatosis. J Investig Med (2001) 0.98
A key angiogenic role of monocyte chemoattractant protein-1 in hemangioendothelioma proliferation. Am J Physiol Cell Physiol (2004) 0.96
Role of monocyte chemoattractant protein-1 and its receptor,CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol (2003) 0.96
Involvement of macrophage chemotactic protein-1 and interleukin-1beta during inflammatory but not basic fibroblast growth factor-dependent neovascularization in the mouse cornea. Lab Invest (2003) 0.94
Tumor-associated macrophages and dendritic cells as prototypic type II polarized myeloid populations. Tumori (2004) 0.90
Anti-monocyte chemoattractant protein-1 gene therapy for cardiovascular diseases. Expert Rev Cardiovasc Ther (2003) 0.87
Loss of expression of tuberin and hamartin in tuberous sclerosis complex-associated but not in sporadic angiofibromas. J Cutan Pathol (2003) 0.85
Cells derived from tuberous sclerosis show a prolonged S phase of the cell cycle and increased apoptosis. Arch Dermatol Res (2001) 0.84
Adjunctive rapamycin and CsA treatment inhibits monocyte/macrophage associated cytokines/chemokines in sensitized cardiac graft recipients. Transplantation (2001) 0.84
TSC1 and TSC2: genes that are mutated in the human genetic disorder tuberous sclerosis. Biochem Soc Trans (2003) 0.83
Compared to mycophenolate mofetil, rapamycin induces significant changes on growth factors and growth factor receptors in the early days post-kidney transplantation. Transplantation (2002) 0.83
Expression of glial fibrillary acidic protein (GFAP) by cultured angiofibroma stroma cells from patients with tuberous sclerosis. Neuropathol Appl Neurobiol (1992) 0.82
Factor XIIIa in the hamartomas of tuberous sclerosis. J Dermatol Sci (1991) 0.80
Potential roles of CCL2/monocyte chemoattractant protein-1 in the pathogenesis of cutaneous sclerosis. Clin Exp Rheumatol (2003) 0.78
Cellular composition of the angiofibromas in tuberous sclerosis. Pediatr Pathol Lab Med (1997) 0.78
Abnormal division and gene expression in cultured cells from a patient with tuberous sclerosis. J Dermatol (1989) 0.77
A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med (2011) 8.26
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74
Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med (2008) 4.33
The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med (2005) 4.15
Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med (2012) 3.42
Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science (2013) 3.40
Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med (2011) 2.67
Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest (2004) 2.27
Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci U S A (2004) 2.27
Serum apolipoprotein A-I and large high-density lipoprotein particles are positively correlated with FEV1 in atopic asthma. Am J Respir Crit Care Med (2015) 1.97
Lymphangioleiomyomatosis. Cancer Control (2006) 1.97
Recognition of tuberous sclerosis in adult women: delayed presentation with life-threatening consequences. Ann Intern Med (2011) 1.92
Cutaneous manifestations of proteus syndrome: correlations with general clinical severity. Arch Dermatol (2004) 1.91
Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase. J Biol Chem (2005) 1.83
Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am J Respir Crit Care Med (2003) 1.78
Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat Genet (2012) 1.74
Prevalence of tuberous sclerosis complex in Taiwan: a national population-based study. Neuroepidemiology (2009) 1.71
Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med (2013) 1.69
Pneumothorax after air travel in lymphangioleiomyomatosis, idiopathic pulmonary fibrosis, and sarcoidosis. Chest (2009) 1.64
A clinical assessment of the Mucus Shaver: a device to keep the endotracheal tube free from secretions. Crit Care Med (2012) 1.57
Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis. Am J Respir Crit Care Med (2014) 1.48
Neonatal incubators: a toxic sound environment for the preterm infant?*. Pediatr Crit Care Med (2012) 1.45
The brefeldin A-inhibited guanine nucleotide-exchange protein, BIG2, regulates the constitutive release of TNFR1 exosome-like vesicles. J Biol Chem (2007) 1.44
Helicobacter pylori vacuolating cytotoxin induces activation of the proapoptotic proteins Bax and Bak, leading to cytochrome c release and cell death, independent of vacuolation. J Biol Chem (2006) 1.43
ADP ribosylation of human neutrophil peptide-1 regulates its biological properties. Proc Natl Acad Sci U S A (2002) 1.34
Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features. Radiology (2006) 1.32
Protein kinase A-anchoring (AKAP) domains in brefeldin A-inhibited guanine nucleotide-exchange protein 2 (BIG2). Proc Natl Acad Sci U S A (2003) 1.32
Unfolded protein response and cell death after depletion of brefeldin A-inhibited guanine nucleotide-exchange protein GBF1. Proc Natl Acad Sci U S A (2008) 1.31
Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest (2009) 1.28
Identification in traditional herbal medications and confirmation by synthesis of factors that inhibit cholera toxin-induced fluid accumulation. Proc Natl Acad Sci U S A (2002) 1.27
The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. Lymphat Res Biol (2010) 1.27
Association of brefeldin A-inhibited guanine nucleotide-exchange protein 2 (BIG2) with recycling endosomes during transferrin uptake. Proc Natl Acad Sci U S A (2006) 1.25
Oral findings in 58 adults with tuberous sclerosis complex. J Am Acad Dermatol (2007) 1.22
The 39-kDa poly(ADP-ribose) glycohydrolase ARH3 hydrolyzes O-acetyl-ADP-ribose, a product of the Sir2 family of acetyl-histone deacetylases. Proc Natl Acad Sci U S A (2006) 1.21
Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms. Proc Natl Acad Sci U S A (2009) 1.21
Progressive overgrowth of the cerebriform connective tissue nevus in patients with Proteus syndrome. J Am Acad Dermatol (2010) 1.21
GEP100/BRAG2: activator of ADP-ribosylation factor 6 for regulation of cell adhesion and actin cytoskeleton via E-cadherin and alpha-catenin. Proc Natl Acad Sci U S A (2006) 1.20
TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis. Cancer Res (2007) 1.18
Helicobacter pylori VacA-induced inhibition of GSK3 through the PI3K/Akt signaling pathway. J Biol Chem (2008) 1.17
Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis. Am J Respir Crit Care Med (2010) 1.17
Favorable response to antigonadal therapy for a benign metastasizing leiomyoma. Obstet Gynecol (2012) 1.16
ARL4D recruits cytohesin-2/ARNO to modulate actin remodeling. Mol Biol Cell (2007) 1.16
Auto-ADP-ribosylation of Pseudomonas aeruginosa ExoS. J Biol Chem (2002) 1.16
Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas. Proc Natl Acad Sci U S A (2008) 1.15
A mechanism for controlled access to GWAS data: experience of the GAIN Data Access Committee. Am J Hum Genet (2013) 1.15
Helicobacter pylori VacA activates the p38/activating transcription factor 2-mediated signal pathway in AZ-521 cells. J Biol Chem (2003) 1.15
Identification and characterization of receptors for vacuolating activity of subtilase cytotoxin. Mol Microbiol (2006) 1.15
Protein-tyrosine phosphatase alpha, RPTP alpha, is a Helicobacter pylori VacA receptor. J Biol Chem (2003) 1.14
Acral lesions in tuberous sclerosis complex: insights into pathogenesis. J Am Acad Dermatol (2010) 1.13
Clinical and molecular insights into lymphangioleiomyomatosis. Sarcoidosis Vasc Diffuse Lung Dis (2005) 1.13
E3 ubiquitin ligase activity of the trifunctional ARD1 (ADP-ribosylation factor domain protein 1). Proc Natl Acad Sci U S A (2005) 1.11
Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis. Chest (2007) 1.09
Interaction of BIG2, a brefeldin A-inhibited guanine nucleotide-exchange protein, with exocyst protein Exo70. Proc Natl Acad Sci U S A (2005) 1.09
An official American Thoracic Society Policy statement: managing conflict of interest in professional societies. Am J Respir Crit Care Med (2009) 1.09
Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion. PLoS One (2012) 1.08
Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-gamma is regulated by mammalian target of rapamycin. J Biol Chem (2003) 1.07
Pleiotropic actions of Helicobacter pylori vacuolating cytotoxin, VacA. Tohoku J Exp Med (2010) 1.07
Regulation of brefeldin A-inhibited guanine nucleotide-exchange protein 1 (BIG1) and BIG2 activity via PKA and protein phosphatase 1gamma. Proc Natl Acad Sci U S A (2007) 1.07
Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. Hum Mol Genet (2013) 1.06
Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene. J Immunol (2009) 1.05
LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cell Mol Life Sci (2012) 1.04
Gangliosides act as co-receptors for Salmonella enteritidis FliC and promote FliC induction of human beta-defensin-2 expression in Caco-2 cells. J Biol Chem (2004) 1.03
Subtilase cytotoxin, produced by Shiga-toxigenic Escherichia coli, transiently inhibits protein synthesis of Vero cells via degradation of BiP and induces cell cycle arrest at G1 by downregulation of cyclin D1. Cell Microbiol (2007) 1.03
Low-density lipoprotein receptor-related protein-1 (LRP1) mediates autophagy and apoptosis caused by Helicobacter pylori VacA. J Biol Chem (2012) 1.03
Cybr, a cytokine-inducible protein that binds cytohesin-1 and regulates its activity. Proc Natl Acad Sci U S A (2002) 1.02
Interaction of FK506-binding protein 13 with brefeldin A-inhibited guanine nucleotide-exchange protein 1 (BIG1): effects of FK506. Proc Natl Acad Sci U S A (2003) 1.01
ADP-ribosyltransferase-specific modification of human neutrophil peptide-1. J Biol Chem (2006) 1.01
Genetic and morphologic determinants of pneumothorax in lymphangioleiomyomatosis. Am J Physiol Lung Cell Mol Physiol (2007) 1.01
Two distinct cytotoxic activities of subtilase cytotoxin produced by shiga-toxigenic Escherichia coli. Infect Immun (2006) 1.01
Pulmonary lymphangiomatosis. Lymphat Res Biol (2011) 1.01
Motor speech perception modulates the cortical language areas. Neuroimage (2008) 1.00
Nuclear localization and molecular partners of BIG1, a brefeldin A-inhibited guanine nucleotide-exchange protein for ADP-ribosylation factors. Proc Natl Acad Sci U S A (2004) 1.00
CT of sclerotic bone lesions: imaging features differentiating tuberous sclerosis complex with lymphangioleiomyomatosis from sporadic lymphangioleiomymatosis. Radiology (2010) 1.00